714 related articles for article (PubMed ID: 20664274)
1. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
[TBL] [Abstract][Full Text] [Related]
2. Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Bodzenta-Lukaszyk A
Adv Med Sci; 2011; 56(2):318-22. PubMed ID: 21940268
[TBL] [Abstract][Full Text] [Related]
3. RANTES in exhaled breath condensate of stable and unstable asthma patients.
Zietkowski Z; Tomasiak MM; Skiepko R; Bodzenta-Lukaszyk A
Respir Med; 2008 Aug; 102(8):1198-202. PubMed ID: 18603420
[TBL] [Abstract][Full Text] [Related]
4. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
[TBL] [Abstract][Full Text] [Related]
5. Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma.
Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Bodzenta-Lukaszyk A
Respiration; 2010; 80(6):534-42. PubMed ID: 20588001
[TBL] [Abstract][Full Text] [Related]
6. Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment.
Yalcin AD; Gorczynski RM; Parlak GE; Kargi A; Bisgin A; Sahin E; Kose S; Gumuslu S
Clin Lab; 2012; 58(1-2):89-96. PubMed ID: 22372350
[TBL] [Abstract][Full Text] [Related]
7. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study.
Tajiri T; Niimi A; Matsumoto H; Ito I; Oguma T; Otsuka K; Takeda T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Izuhara Y; Mishima M
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):470-5.e2. PubMed ID: 24994694
[TBL] [Abstract][Full Text] [Related]
9. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory markers and acid-base equilibrium in exhaled breath condensate of stable and unstable asthma patients.
Tomasiak-Lozowska MM; Zietkowski Z; Przeslaw K; Tomasiak M; Skiepko R; Bodzenta-Lukaszyk A
Int Arch Allergy Immunol; 2012; 159(2):121-9. PubMed ID: 22653320
[TBL] [Abstract][Full Text] [Related]
14. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
Hanania NA; Wenzel S; Rosén K; Hsieh HJ; Mosesova S; Choy DF; Lal P; Arron JR; Harris JM; Busse W
Am J Respir Crit Care Med; 2013 Apr; 187(8):804-11. PubMed ID: 23471469
[TBL] [Abstract][Full Text] [Related]
15. The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients.
Pasha MA; Jourd'heuil D; Jourd'heuil F; Mahon L; Romero F; Feustel PJ; Evans M; Smith T; Mitchell J; Gendapodi P; Demeyere-Coursey KC; Townley RG
Allergy Asthma Proc; 2014; 35(3):241-9. PubMed ID: 24801467
[TBL] [Abstract][Full Text] [Related]
16. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
Busse WW; Massanari M; Kianifard F; Geba GP
Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma.
Takaku Y; Soma T; Nishihara F; Nakagome K; Kobayashi T; Hagiwara K; Kanazawa M; Nagata M
Int Arch Allergy Immunol; 2013; 161 Suppl 2():107-17. PubMed ID: 23711861
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
[TBL] [Abstract][Full Text] [Related]
19. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
[TBL] [Abstract][Full Text] [Related]
20. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
Dewilde S; Turk F; Tambour M; Sandström T
Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
